Colicin E9: Difference between revisions
| Line 3: | Line 3: | ||
==Synthesis and release== | ==Synthesis and release== | ||
{{STRUCTURE_1emv | PDB=1emv | SCENE= Colicin_E9/Cole9dnaseim9/1 }} | {{STRUCTURE_1emv | PDB=1emv | SCENE= Colicin_E9/Cole9dnaseim9/1 }} | ||
Colicin E9 in solution, ie in the cytoplasm after synthesis, is monomeric, and forms a high affinity complex with its immunity protein, [[Im9]]. The immunity protein does not directly bind to the active site, but instead to an exosite. This is bound while in the producing cell to protect it from the activity<ref> PMID: 15044477 </ref>. The structure shown is that of the <scene name='Colicin_E9/Cole9dnas/1'>DNase domain</scene> of colicin E9 bound to Im9<ref> PMID: 10966813 </ref>. | Colicin E9 in solution, ie in the cytoplasm after synthesis, is monomeric, and forms a high affinity complex with its immunity protein, [[Im9]]. The immunity protein does not directly bind to the active site, but instead to an exosite. This is bound while in the producing cell to protect it from the activity<ref> PMID: 15044477 </ref>. The structure shown is that of the <scene name='Colicin_E9/Cole9dnas/1'>DNase domain</scene> of colicin E9 bound to <scene name='Colicin_E9/Im9/2'>Im9</scene><ref> PMID: 10966813 </ref>. | ||
==Mechanism of uptake== | ==Mechanism of uptake== | ||